ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly endocrinology therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2019] ($M)
Form 10-K Note 2 (legacy Endocrinology grouping)
Latest, Q3 2019
3,144
Period ended Sep 30, 2019
Change on a year earlier
+10.8%
2,838 in Q3 2018
History
24 quarters
Since Q2 2012
Sources
19
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Endocrinology therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2019] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2019 | Sep 30, 2019 | 3,144 | +10.8% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2019 | Jun 30, 2019 | 3,207 | +8.5% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2019 | Mar 31, 2019 | 2,930 | +8.6% | Form 10-Q (filed 2019-05-02) ↗ |
| Q3 2018 | Sep 30, 2018 | 2,838 | +10.8% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 2,955 | +18.6% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 2,699 | +27.1% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 2,910 | – | Form 10-K (filed 2018-02-20) ↗ |
| Q3 2017 | Sep 30, 2017 | 2,561 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 2,491 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 2,123 | +20.9% | Form 10-Q (filed 2018-04-27) ↗ |
| Q1 2016 | Mar 31, 2016 | 1,757 | +8.0% | Form 10-Q (filed 2016-04-29) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,986 | +7.2% | Form 10-K (filed 2016-02-19) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,786 | +4.6% | Form 10-Q (filed 2015-10-30) ↗ |
| Q2 2015 | Jun 30, 2015 | 1,638 | -5.8% | Form 10-Q (filed 2015-07-30) ↗ |
| Q1 2015 | Mar 31, 2015 | 1,626 | -0.8% | Form 10-Q (filed 2015-04-30) ↗ |
| Q4 2014 | Dec 31, 2014 | 1,852 | – | Form 10-K (filed 2015-02-19) ↗ |
| Q3 2014 | Sep 30, 2014 | 1,708 | – | Form 10-Q (filed 2014-10-29) ↗ |
| Q2 2014 | Jun 30, 2014 | 1,740 | -2.5% | Form 10-Q (filed 2014-07-28) ↗ |
| Q1 2014 | Mar 31, 2014 | 1,639 | -5.0% | Form 10-Q (filed 2014-04-28) ↗ |
| Q2 2013 | Jun 30, 2013 | 1,784 | +4.7% | Form 10-Q (filed 2013-07-26) ↗ |
| Q1 2013 | Mar 31, 2013 | 1,725 | – | Form 10-Q (filed 2014-04-28) ↗ |
| Q4 2012 | Dec 31, 2012 | 1,770 | – | Form 10-K (filed 2014-02-19) ↗ |
| Q3 2012 | Sep 30, 2012 | 1,646 | – | Form 10-Q (filed 2013-10-30) ↗ |
| Q2 2012 | Jun 30, 2012 | 1,704 | – | Form 10-Q (filed 2013-07-26) ↗ |
Breakdown
What makes up endocrinology therapeutic area — worldwide revenue ($m) [legacy grouping through fy2019]
Cite this data
StockData. (2026). Eli Lilly Endocrinology therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2019] ($M), quarterly Q2 2012–Q3 2019 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_endocrinology_ww_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.